Unconventional End Points in Cardiovascular Clinical Trials: Should We Be Moving Away From Morbidity and Mortality?

Journal of Cardiac Failure

Volumn 15, Issue 3, 2009, Pages 199-205

  Cohn, Jay ^a   Cleland, John G F ^b   Lubsen, Jacobus ^c   Borer, Jeffrey S ^d   Steg, Philippe Gabriel ^e   Perelman, Michael ^f   Zannad, Faiez ^g  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF HULL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e INSERM   (France)

^f MERCK RESEARCH LABORATORIES   (United States)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Clinical trials; morbidity; mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CARDIOVASCULAR RISK; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG LABELING; ENDPOINT DETERMINATION; HOSPITALIZATION; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; VENTRICULAR REMODELING;

EID: 62649138687     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.10.029     Document Type: Article

References (33)

1. Neaton J.D., Gray G., Zuckerman B.D., and Konstam M.A. Key issues in end point selection for heart failure trials: composite end points. J Card Fail 11 (2005) 567-575
2. Taylor A.L., Ziesche S., Yancy C., Carson P., D'Agostino Jr. R., Ferdinand K., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
3. Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
4. Poole-Wilson P.A., Lubsen J., Kirwan B.A., van Dalen F.J., Wagener G., Danchin N., et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 364 (2004) 849-857
5. Lubsen J., and Kirwan B.A. Combined end points: can we use them?. Stat Med 21 (2002) 2959-2970
6. Ziesche S., Rector T.S., and Cohn J.N. Interobserver discordance in the classification of mechanisms of death in studies of heart failure. J Cardiac Fail 1 (1995) 127-132
7. Cohn J.N. Efficacy and safety in clinical trials in cardiovascular disease. J Am Coll Cardiol 48 (2006) 430-433
8. Solomon S.D., Wang D., Finn P., Skali H., Zornoff L., McMurray J.J., et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 110 (2004) 2180-2183
9. Poole-Wilson P.A., Swedberg K., Cleland J.G., Di L.A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362 (2003) 7-13
10. Dickstein K., and Kjekshus J. OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
11. Investigators II C.I.B.I.S. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
12. Carson P., Tognoni G., and Cohn J.N. Effect of valsartan on hospitalization: results from Val-HeFT. J Card Fail 9 (2003) 164-171
13. Cleland J.G., and Atkin S.L. Thiazolidinediones, deadly sins, surrogates, and elephants. Lancet 370 (2007) 1103-1104
14. Lewis E.F., Johnson P.A., Johnson W., Collins C., Griffin L., and Stevenson L.W. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 20 (2001) 1016-1024
15. Braunwald E., Cannon C.P., and McCabe C.H. Use of composite end points in thrombolysis trials of acute myocardial infarction. Am J Cardiol 72 (1993) 3G-12G
16. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail 7 (2001) 176-182
17. Cleland J.G. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 4 (2002) 243-247
18. Cleland J.G., Charlesworth A., Lubsen J., Swedberg K., Remme W.J., Erhardt L., et al. A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol 47 (2006) 1603-1611
19. Olsson G., Lubsen J., van Es G.A., and Rehnqvist N. Quality of life after myocardial infarction: effect of long term metoprolol on mortality and morbidity. Br Med J(Clin Res Ed) 292 (1986) 1491-1493
20. Cohn J.N., Ferrari R., and Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35 (2000) 569-582
21. Cohn J.N. Remodeling as an end-point in heart failure therapy. Cardiovasc Drugs Ther 18 (2004) 7-8
22. Cohn J.N., Hoke L., Whitwam W., Sommers P.A., Taylor A.L., Duprez D., et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J 146 (2003) 679-685
23. Duprez D.A., Florea N.D., Jones K., and Cohn J.N. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol 50 (2007) 835-839
24. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
25. Goode K.M., Clark A.L., Bristow J.A., Sykes K.B., and Cleland J.G. Screening for left ventricular systolic dysfunction in high-risk patients in primary-care: a cost-benefit analysis. Eur J Heart Fail 9 (2007) 1186-1195
26. Cohn J.N., Pfeffer M.A., Rouleau J., Sharpe N., Swedberg K., Straub M., et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 5 (2003) 659-667
27. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 (1989) 406-412
28. Psaty B.M., and Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA 299 (2008) 1474-1476
29. Barter P.J., Caulfield M., Eriksson M., Grundy S.M., Kastelein J.J., Komajda M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
30. Greenland P., and Lloyd-Jones D. Critical lessons from the ENHANCE trial. JAMA 299 (2008) 953-955
31. Kastrati A., Mehilli J., and Pache J. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
32. Barnett D.B. Flosequinan. Lancet 341 (1993) 733-736
33. Ferreira-Gonzalez I., Busse J.W., Heels-Ansdell D., Montori V.M., Akl E.A., Bryant D.M., et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ 334 (2007) 786